Read More

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV